Emerging therapies of hepatitis B and C.
Chen
Robert Y M
RY
Victorian Infectious Diseases Reference Laboratory and St Vincent's Hospital,Melbourne, Victoria, Australia.
Desmond
Paul V
PV
Locarnini
Stephen A
SA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors